A Phase 1 Clinical Study of NXP900 in Subjects With Advanced Cancers

StatusActive, Not Recruiting
PhasePhase 1
Started

Free. We email you which fields changed when ClinicalTrials.gov updates this record.

Track this trial
View on ClinicalTrials.gov ↗

Record History

See every version on ClinicalTrials.gov ↗

  1. Primary endpoints: details revised at 1 of 5 entries Show 5 more changesShow less
    • Enrollment closed, study ongoing
    • Eligibility criteria expanded, about 33 words
    • Secondary endpoints: details revised at 3 of 6 entries
    • Site details revised at 15 of 15 sites
    • Publications: details revised at 1 of 1 entry
  2. Trial sites expanded: 12 → 15 locations
    • Eligibility criteria expanded, about 18 words
    v14
  3. Study sites: 7 to 12v13
  4. Enrollment target: 40 to 140v12 Show 8 more changesShow less
    • Primary completion date: Apr 2025 to Mar 2027
    • Primary endpoints: 2 to 5
    • Study completion date: May 2025 to Jul 2027
    • Eligibility criteria expanded, about 321 words
    • Secondary endpoints: details revised at 6 of 6 entries
    • Study description shortened, about 25 words
    • Site details revised at 2 of 7 sites
    • Study arms: 1 to 2
  5. Primary completion date: Jan 2025 to Apr 2025
    • Study completion date: Apr 2025 to May 2025
    • Study sites revised (7)
    v11
Show 9 earlier versionsHide 9 earlier versions
  1. Primary completion date: Sep 2024 to Jan 2025
    • Study completion date: Jan 2025 to Apr 2025
    • Site contacts updated at 2 of 7 sites
    v10
  2. Study sites: 6 to 7v9
  3. Study sites: 4 to 6v8
  4. Study sites: 3 to 4v7
  5. Study sites: 2 to 3v6
  6. Site details revised at 1 of 2 sitesv5
  7. Start date changed from estimate of Oct 2023 to Oct 26, 2023v4
  8. Study sites: 1 to 2v3
  9. Trial status: Not Yet Recruiting to Recruiting
    • Start date: Jun 2023 to Oct 2023
    • Study sites: 0 to 1
    v2
  1. Study First Submitted
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
Nuvectis Pharma, Inc.
4 trials monitored
See all monitored trials
Lung Cancer
4,798 trials monitored
See 270 trials at risk
Non-Small Cell Lung Cancer (NSCLC)
3,085 trials monitored
See 178 trials at risk
Kidney Cancer
890 trials monitored
See 72 trials at risk
and 1 more disease
This is a multi-center, first-in-human, open label, dose escalation (Part A) and expansion (Part B) Phase 1 study in subjects with advanced solid tumors and in subjects with solid tumors with selected genetic alterations that are either direct (YES1 amplification) or dependent (Hippo Pathway alterations) targets of NXP900.
Trial Details
NCT Number NCT05873686
Lead Sponsor Nuvectis Pharma, Inc.
Conditions
(from sponsor)		 Advanced Solid Tumor, NSCLC (Non-small Cell Lung Cancer), Renal Cancer, Mesothelioma, Non-Small Cell Squamous Lung Cancer, Non-small Cell Lung Adenocarcinoma
Related terms Adenocarcinoma, Carcinoma, Carcinoma, Non-Small-Cell Lung, Kidney Neoplasms, Mesothelioma, Neoplasms
Enrollment 140 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov